Comparative analysis of Russian and international requirements for soft dosage forms

DOI: https://doi.org/10.29296/25419218-2024-04-05
Issue: 
4
Year: 
2024

N.V. Avtina(1), A.V. Prasolova(1, 2), E.T. Zhilyakova(1), T.N. Glizhova(2)
1-Belgorod State National Research University, st. Pobeda, 85, Belgorod, 308015, Russian Federation;
2-North-Caucasus Federal University, st. Pushkina, 1, Stavropol, 355017, Russian Federation

Introduction. In the Russian Federation, the latest version of the State Pharmacopoeia, XV edition, has been developed and is actively used. (entered into force on September 1, 2023). However, when developing and introducing various medicines into production, pharmaceutical services are forced to turn to GMP and GLP standards to bring the requirements into compliance with European standards. In this connection, it is relevant to conduct a comparative analysis of the regulatory requirements imposed, in particular, on soft dosage forms, in order to identify their similarities and differences. The established differential features specified in the General Pharmacopoeial Article «Soft Dosage Forms» (GF XV ed., OFS.1.4.1.0008) and foreign pharmacopoeial articles will allow pharmaceutical specialists to harmonize the requirements and use them in the pharmaceutical development and standardization of dosage forms in the form of gels , creams, liniments, ointments, pastes. Objective: comparative analysis of Russian and international pharmacopoeial requirements for soft dosage forms to identify differential features and develop proposals for harmonizing quality indicators in accordance with modern standards. Material and methods. The main materials for carrying out the information and analytical research method were the requirements reflected in domestic and foreign regulatory documentation that controls the quality of soft dosage forms. To solve the problems, we used materials from monographs of six leading pharmacopoeias, including foreign ones – State Pharmacopoeia of the Russian Federation XV ed. (SF RF), State Pharmacopoeia of the Republic of Belarus (SP RB), Pharmacopoeia of the Eurasian Economic Union (Ph. Eur.), British Pharmacopoeia (Ph. Br.), Chinese Pharmacopoeia (Ch. Ph.), Indian Pharmacopoeia (Ind. Ph.) and Ayurvedic Pharmacopoeia 2010 (Ayur. Ph.). Results. A comparative study of pharmacopoeial requirements for the characteristics and quality indicators of soft dosage forms presented in the State Pharmacopoeia of the Russian Federation XV (2023), State Pharmacopoeia of the Republic of Belarus (2013, 2016), Pharmacopoeia of the Eurasian Economic Union (2020) was carried out, Ph. Br. (2020), Chinese Pharmacopoeia (2020), Indian Pharmacopoeia (2022) and Ayurvedic Pharmacopoeia (2010). The analysis showed differences in approaches to standardization and quality control of soft dosage forms in leading pharmacopoeias. The results of the study can be used in the pharmaceutical development and standardization of soft dosage forms, as well as in adjusting the General Pharmacopoeia Monograph “Soft dosage forms”. Differences in pharmacopoeial requirements, reflected in Pharmacopoeial monographs, have been identified in the development and quality control of soft dosage forms. Conclusion. The fundamental differential features of regulatory requirements have been identified, making it possible to formulate changes and additions to the General Pharmacopoeia Monograph «Soft dosage forms» during their pharmaceutical development and standardization.
Keywords: 
pharmacopoeial requirements
soft dosage forms
quality indicators.
References: 
  1. Ниязов Р.Р., Васильев А.Н., Гавришина Е.В., Драницына М.А. Качество лекарственных препаратов: связь нормативной документации со спецификацией, регистрационным досье, фармакопеей и GMP. Ремедиум. 2017; 4. [Niyazov R.R., Vasiliev A.N., Gavrishina E.V., Dranitsyna M.A. Quality of medicinal products: connection of regulatory documentation with specifications, registration dossier, pharmacopoeia and GMP. Remedium. 2017; 4 (in Russian)].
  2. De A. et al. Pharmacopoeias, national formulary and extra pharmacopoeia. Dosage Forms, Formulation Developments and Regulations. Academic Press. 2024; 83–98.
  3. Shishova L.I., Sakanyan E.I., Shemeryankina T.B. et al. Pharmacopoeial Quality Requirements for Compounded Pharmaceuticals: Present and Future. Pharm Chem J. 2017; 51: 731–4. https://doi.org/10.1007/s11094-017-1683-3
  4. Колесникова С.С., Василенко М.А. Государственное управление и государственное регулирование в здравоохранении. Компетентность. 2024; 1. [Kolesnikova S.S., Vasilenko M.A. Public administration and state regulation in healthcare. Competence. 2024; 1 (in Russian)].
  5. Ковалева Е.Л., Золотов Ю.А., Сомов Д.В. Обеспечение качества лекарственных средств: основные научные подходы и методы контроля. Ведомости Научного центра экспертизы средств медицинского применения. Регуляторные исследования и экспертиза лекарственных средств. 2023; 13 (3): 368–75. [Kovaleva E.L., Zolotov Yu.A., Somov D.V. Ensuring the quality of medicines: basic scientific approaches and control methods. Gazette of the Scientific Center for Expertise of Medical Products. Regulatory research and examination of medicines. 2023; 13 (3): 368–75. DOI: 10.30895/1991-2919-2023-13-3-368-375 (in Russian)].
  6. Sakanyan E.I., Shemeryankina T.B., Osipova I.G. et al. Establishment of Pharmacopoeial Quality Standards for the State Pharmacopoeia of the Russian Federation. Pharm Chem J. 2017; 51: 136–41. https://doi.org/10.1007/s11094-017-1572-9
  7. Гаммель И.В., Жукова О.В., Кононова С.В., Коннова М.А. Исследование ассортимента лекарственных средств в лекарственной форме мази. Вопросы биологической, медицинской и фармацевтической химии. 2019; 22 (8): 3−9. [Gammel I.V., Zhukova O.V., Kononova S.V., Konnova M.A. Study of the range of medicines in ointment dosage form. Questions of biological, medical and pharmaceutical chemistry. 2019; 22 (8): 3−9. DOI: 10.29296/25877313-2019-08-01 (in Russian)].
  8. Zurada J.M., Kriegel D., Davis I.C. Topical treatments for hypertrophic scars. J. Am. Acad Dermatol. 2006; 55 (6): 1024–31. DOI: 10.1016/j.jaad.2006.03.022. Epub 2006 Sep 18. PMID: 17097399.
  9. Жилякова Е.Т., Иващенкова А.О. Анализ российского фармацевтического рынка лекарственных препаратов для лечения термических ожогов. Текст: непосредственный. Молодой ученый. 2017; 39 (173): 8–11. [Zhilyakova E.T., Ivashchenkova A.O. Analysis of the Russian pharmaceutical market of drugs for the treatment of thermal burns. Text: immediate. Young scientist. 2017; 39 (173): 8–11 (in Russian)].
  10. Зверева В.И., Семкина О.А., Джавахян М.А. Анализ ассортимента мягких лекарственных форм для приема внутрь, содержащих субстанции растительного происхождения. Вопросы биологической, медицинской и фармацевтической химии. 2020; 23 (5): 37–44. [Zvereva V.I., Semkina O.A., Javakhyan M.A. Analysis of the assortment of soft dosage forms for oral administration containing substances of plant origin. Questions of biological, medical and pharmaceutical chemistry. 2020; 23 (5): 37–44. DOI: 10.29296/25877313-2020-05-06 (in Russian)].
  11. Овод А.И., Зюкин Д.А., Мамаев А.А. Конъюктура фармацевтического рынка России. Вестник Алтайской академии экономики и права. 2022; 3–2: 242–7. [Ovod A.I., Zyukin D.A., Mamaev A.A. Conjuncture of the Russian pharmaceutical market. Bulletin of the Altai Academy of Economics and Law. 2022; 3–2: 242–7 (in Russian)].
  12. Мальцев Е.А., Колесников А.С., Филина И.А. Актуальные вопросы системы менеджмента качества в фармацевтическом производстве. Здоровье и образование в XXI веке. 2023; 6. [Maltsev E.A., Kolesnikov A.S., Filina I.A. Current issues of the quality management system in pharmaceutical production. Health and education in the XXI century. 2023; 6 (in Russian)].
  13. Yarutkin A.V., Bagirova V.I. Provisions of the National and EEU Legislation on Pharmacopoeia: Updating and Prospects of Development. Pharm. Chem. J. 2023; 56: 1400–6. https://doi.org/10.1007/s11094-023-02804-5
  14. Michael Ljungberg: Handbook of Nuclear Medicine and Molecular Imaging for Physicists Volume III: Radiopharmaceuticals and Clinical Applications, Boca Raton, FL, USA: CRC Press Taylor & Francis Group. 2022; 9781138593312: 87–94. DOI: 10.1201/9780429489501-8
  15. Tikhomirova T.M., Solovieva E.V. Retail segment of the Russian pharmaceutical market development trends. Information Innovative Technologies: International Scientific – Practical Conference, Prague, 26–30 апреля 2021 года. Moscow: Association of graduates and employees of AFEA named after prof. Zhukovsky, 2021; 333–8. EDN HIXQXY.
  16. Lobuteva L., Lobuteva A., Zakharova O. et al. The modern Russian pharmaceutical market: consumer attitudes towards distance retailing of medicines. BMC Health Serv Res. 2022; 22: 582. https://doi.org/10.1186/s12913-022-07991-7
  17. Суханова С.М., Минаева Н.М. Сравнительный анализ отечественных и зарубежных фармакопейных требований к оценке качества воды для инъекций: проблемы и пути гармонизации. БИОпрепараты. Профилактика, диагностика, лечение. 2019; 19 (2): 99–108. [Sukhanova S.M., Minaeva N.M. Comparative analysis of domestic and foreign pharmacopoeial requirements for assessing the quality of water for injection: problems and ways of harmonization. BIOpreparations. Prevention, diagnosis, treatment. 2019; 19 (2): 99–108. DOI: 10.30895/2221-996X-2019-19-2-99-108 (in Russian)].